Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The plant is scheduled to come on stream in September 2024
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Subscribe To Our Newsletter & Stay Updated
